PUBLISHER: Grand View Research | PRODUCT CODE: 2067468
PUBLISHER: Grand View Research | PRODUCT CODE: 2067468
The global enclomiphene market size was estimated at USD 216.00 million in 2025 and is projected to reach USD 419.05 million by 2033, growing at a CAGR of 8.70% from 2026 to 2033. The growth is driven by the increasing prevalence of male hypogonadism and infertility, along with a growing preference for therapies that boost endogenous testosterone while preserving fertility.
Rising awareness of men's health, improved diagnosis rates, and expanding access to fertility and endocrinology care are further supporting demand. In addition, the shift toward selective estrogen receptor modulators over traditional testosterone replacement therapy, coupled with ongoing clinical research, product development, and lifestyle factors such as delayed parenthood and hormonal imbalances, is accelerating market growth, although regulatory constraints and competition from established treatments like clomiphene citrate may moderate adoption.
The enclomiphene segment has seen increasing clinical and patient interest as a non steroidal medium dose (12.5 mg - 25 mg) therapy that stimulates the body's own testosterone production while preserving fertility, positioning it as an alternative for men with hypogonadism who wish to avoid the suppressive effects of traditional testosterone replacement therapy (TRT). Enclomiphene works by blocking estrogen receptors in the hypothalamus and boosting luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which, in turn, elevate endogenous testosterone levels without shutting down the hypothalamic-pituitary-gonadal axis. Recent clinical data, including a 2025 - 2026 systematic review/meta-analysis of randomized controlled trials, confirmed that selective estrogen receptor modulators like enclomiphene significantly improve testosterone, LH, and FSH levels in men with functional hypogonadism, offering potential benefits over placebo and comparable hormonal effects to topical testosterone, with the added advantage of fertility preservation.
The segment's growth is driven by a rising prevalence of male hypogonadism, increasing demand for fertility sparing testosterone therapies, and patient preference for medium dose (12.5 mg - 25 mg) treatments that avoid injections and the systemic suppression associated with traditional TRT. Metabolic and lifestyle factors such as obesity and type 2 diabetes, which contribute to secondary hypogonadism, are further fueling interest in alternatives like enclomiphene that target underlying hormonal axis dysfunction. Clinical studies and meta-analyses have demonstrated that enclomiphene and similar selective estrogen receptor modulators (SERMs) not only effectively raise testosterone levels but also preserve spermatogenesis better than conventional testosterone therapies. These advantages make it a preferred option for men seeking both efficacy and fertility preservation. Growing awareness among healthcare providers and patients regarding long-term safety and quality-of-life benefits is further supporting adoption. As more real-world use and incremental research emerge, the segment continues to expand, emphasizing patient-centered hormonal management.
Global Enclomiphene Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global enclomiphene market report based on product type, dosage strength, indication, distribution channel, and region: